VIDEO: Sacituzumab govitecan delays subsequent therapy in breast cancer subset

CHICAGO — In this video, Sara A. Hurvitz, MD, FACP, discusses the ASCENT-03 study, which showed treatment with sacituzumab govitecan improved PFS and delayed subsequent therapy vs. chemotherapy in metastatic triple-negative breast cancer.Results of the trial, which compared sacituzumab govitecan (Trodelvy, Gilead Sciences) with chemotherapy in previously untreated patients who were